STING ablation in T cells is required for the efficacy of STING agonists in CAR-T cell immunotherapy of pancreatic cancer - PubMed
7 days ago
- #STING agonists
- #Pancreatic cancer
- #CAR-T cells
- STING ablation in CAR-T cells enhances efficacy when combined with STING agonists in pancreatic cancer therapy.
- Combination of STING-ablated CAR-T cells and diABZI (STING agonist) improves cancer cell killing and reduces T cell exhaustion.
- Superior CAR-T cell functionality depends on genetic STING ablation and cancer cell-intrinsic STING signaling.
- A synergistic feedback loop involving IFN-γ and TNF enhances STING signaling in cancer cells, improving CAR-T cell states.
- STINGKO CAR-T cells with diABZI show enhanced tumor control in mouse models, increasing intratumoral CAR-T cell numbers and reprogramming the tumor microenvironment.